ARWR
Price
$29.07
Change
+$1.08 (+3.86%)
Updated
Sep 5 closing price
Capitalization
4.02B
86 days until earnings call
XOMA
Price
$35.24
Change
-$0.16 (-0.45%)
Updated
Sep 5 closing price
Capitalization
425.97M
61 days until earnings call
Interact to see
Advertisement

ARWR vs XOMA

Header iconARWR vs XOMA Comparison
Open Charts ARWR vs XOMABanner chart's image
Arrowhead Pharmaceuticals
Price$29.07
Change+$1.08 (+3.86%)
Volume$2.72M
Capitalization4.02B
XOMA Royalty
Price$35.24
Change-$0.16 (-0.45%)
Volume$33.36K
Capitalization425.97M
ARWR vs XOMA Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. XOMA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and XOMA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ARWR: $29.08 vs. XOMA: $35.24)
Brand notoriety: ARWR: Notable vs. XOMA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 115% vs. XOMA: 70%
Market capitalization -- ARWR: $4.02B vs. XOMA: $425.97M
ARWR [@Biotechnology] is valued at $4.02B. XOMA’s [@Biotechnology] market capitalization is $425.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMA is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 7 TA indicator(s) are bullish while XOMA’s TA Score has 7 bullish TA indicator(s).

  • ARWR’s TA Score: 7 bullish, 4 bearish.
  • XOMA’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, both ARWR and XOMA are a good buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а +31.98% price change this week, while XOMA (@Biotechnology) price change was +8.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

XOMA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($4.02B) has a higher market cap than XOMA($426M). ARWR YTD gains are higher at: 54.654 vs. XOMA (34.094). XOMA has higher annual earnings (EBITDA): -305K vs. ARWR (-52.51M). ARWR has more cash in the bank: 900M vs. XOMA (83.9M). XOMA has less debt than ARWR: XOMA (115M) vs ARWR (353M). ARWR has higher revenues than XOMA: ARWR (573M) vs XOMA (12.8M).
ARWRXOMAARWR / XOMA
Capitalization4.02B426M944%
EBITDA-52.51M-305K17,215%
Gain YTD54.65434.094160%
P/E RatioN/AN/A-
Revenue573M12.8M4,477%
Total Cash900M83.9M1,073%
Total Debt353M115M307%
FUNDAMENTALS RATINGS
ARWR vs XOMA: Fundamental Ratings
ARWR
XOMA
OUTLOOK RATING
1..100
2426
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10060
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3638
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (2) in the Biotechnology industry is significantly better than the same rating for ARWR (94). This means that XOMA’s stock grew significantly faster than ARWR’s over the last 12 months.

XOMA's Profit vs Risk Rating (60) in the Biotechnology industry is somewhat better than the same rating for ARWR (100). This means that XOMA’s stock grew somewhat faster than ARWR’s over the last 12 months.

XOMA's SMR Rating (96) in the Biotechnology industry is in the same range as ARWR (97). This means that XOMA’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (36) in the Biotechnology industry is in the same range as XOMA (38). This means that ARWR’s stock grew similarly to XOMA’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for XOMA (100). This means that ARWR’s stock grew significantly faster than XOMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRXOMA
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 19 days ago
83%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BLUEX40.560.02
+0.05%
AMG Veritas Global Real Return I
FSIUX28.12N/A
N/A
Invesco Dividend Income R5
MXREX12.38N/A
N/A
Empower Real Estate Index Inv
TRAIX37.93N/A
N/A
T. Rowe Price Capital Appreciation I
FTVZX34.87N/A
N/A
FullerThaler Behav Md-Cp Val R6

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+3.84%
DNLI - ARWR
51%
Loosely correlated
+4.33%
IMNM - ARWR
49%
Loosely correlated
+7.35%
CRNX - ARWR
49%
Loosely correlated
+3.97%
RGNX - ARWR
48%
Loosely correlated
+3.08%
IPSC - ARWR
47%
Loosely correlated
+5.41%
More

XOMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMA has been loosely correlated with SYRE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMA
1D Price
Change %
XOMA100%
-0.45%
SYRE - XOMA
40%
Loosely correlated
+0.06%
OLMA - XOMA
39%
Loosely correlated
+30.87%
ARWR - XOMA
38%
Loosely correlated
+3.84%
RCUS - XOMA
37%
Loosely correlated
+5.45%
FENC - XOMA
37%
Loosely correlated
-1.96%
More